HIV Screening Clinical Guidelines Implementation Guide
0.1.0 - CI Build
Unknown region code '840'
HIV Screening Clinical Guidelines Implementation Guide, published by National Association of Community Health Centers, Inc. (NACHC). This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/hiv-cds/ and changes regularly. See the Directory of published versions
Draft as of 2024-08-12 |
{
"resourceType" : "ValueSet",
"id" : "nachc-b2-de113",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ValueSet nachc-b2-de113</b></p><a name=\"nachc-b2-de113\"> </a><a name=\"hcnachc-b2-de113\"> </a><a name=\"nachc-b2-de113-en-US\"> </a><ul><li>Include these codes as defined in <a href=\"CodeSystem-hiv-custom.html\"><code>http://fhir.org/guides/nachc/hiv-cds/CodeSystem/hiv-custom</code></a><table class=\"none\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE113\">NACHC.B2.DE113</a></td><td>RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)</td><td>Hepatitis C Procedures - RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)</td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE114\">NACHC.B2.DE114</a></td><td>Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)</td><td>Hepatitis C Procedures - Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)</td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE115\">NACHC.B2.DE115</a></td><td>Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)</td><td>Hepatitis C Procedures - Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)</td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE116\">NACHC.B2.DE116</a></td><td>Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)</td><td>Hepatitis C Procedures - Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)</td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE117\">NACHC.B2.DE117</a></td><td>Hepatitis C screening documented as performed (HIV)</td><td>Hepatitis C Procedures - Hepatitis C screening documented as performed (HIV)</td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE118\">NACHC.B2.DE118</a></td><td>Patient receiving antiviral treatment for Hepatitis C (HEP-C)</td><td>Hepatitis C Procedures - Patient receiving antiviral treatment for Hepatitis C (HEP-C)</td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE119\">NACHC.B2.DE119</a></td><td>Collection of venous blood by venipuncture</td><td>Hepatitis C Procedures - Collection of venous blood by venipuncture</td></tr><tr><td><a href=\"CodeSystem-hiv-custom.html#hiv-custom-NACHC.46B2.46DE120\">NACHC.B2.DE120</a></td><td>Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver</td><td>Hepatitis C Procedures - Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver</td></tr></table></li></ul></div>"
},
"url" : "http://fhir.org/guides/nachc/hiv-cds/ValueSet/nachc-b2-de113",
"version" : "0.1.0",
"name" : "HepatitisCProceduresCodes",
"title" : "Hepatitis C Procedures Codes",
"status" : "draft",
"experimental" : false,
"date" : "2024-08-12T19:50:21+00:00",
"publisher" : "National Association of Community Health Centers, Inc. (NACHC)",
"contact" : [
{
"telecom" : [
{
"system" : "url",
"value" : "https://www.nachc.org/"
}
]
}
],
"description" : "Codes representing possible values for the Hepatitis C Procedures element",
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "840"
}
]
}
],
"immutable" : true,
"copyright" : "Copyright National Association of Community Health Centers, Inc. (NACHC)",
"compose" : {
"include" : [
{
"system" : "http://fhir.org/guides/nachc/hiv-cds/CodeSystem/hiv-custom",
"concept" : [
{
"code" : "NACHC.B2.DE113",
"display" : "RNA testing for Hepatitis C documented as performed within 6 months prior to initiation of antiviral treatment for Hepatitis C (HEP-C)"
},
{
"code" : "NACHC.B2.DE114",
"display" : "Hepatitis C quantitative RNA testing documented as performed at 12 weeks from initiation of antiviral treatment (HEP-C)"
},
{
"code" : "NACHC.B2.DE115",
"display" : "Ribonucleic acid (RNA) testing for Hepatitis C viremia ordered or results documented (HEP C)"
},
{
"code" : "NACHC.B2.DE116",
"display" : "Hepatitis C genotype testing documented as performed prior to initiation of antiviral treatment for Hepatitis C (HEP C)"
},
{
"code" : "NACHC.B2.DE117",
"display" : "Hepatitis C screening documented as performed (HIV)"
},
{
"code" : "NACHC.B2.DE118",
"display" : "Patient receiving antiviral treatment for Hepatitis C (HEP-C)"
},
{
"code" : "NACHC.B2.DE119",
"display" : "Collection of venous blood by venipuncture"
},
{
"code" : "NACHC.B2.DE120",
"display" : "Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum, prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver"
}
]
}
]
}
}